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Earlier studies have demonstrated in A/Sn mice highly susceptible to Chagas’ disease protective immunity
against lethal Trypanosoma cruzi infection elicited by vaccination with an open reading frame (ORF) expressed
by amastigotes. In our experiments, we used this mouse model to search for other amastigote-expressed ORFs
with a similar property. Fourteen ORFs previously determined to be expressed in this developmental stage
were individually inserted into a eukaryotic expression vector containing a nucleotide sequence that encoded
a mammalian secretory signal peptide. Immunization with 13 of the 14 ORFs induced specific antibodies which
recognized the amastigotes. Three of those immune sera also reacted with trypomastigotes and epimastigotes.
After a lethal challenge with Y strain trypomastigotes, the vast majority of plasmid-injected mice succumbed
to infection. In some cases, a significant delay in mortality was observed. Only two of these ORFs provided
protective immunity against the otherwise lethal infection caused by trypomastigotes of the Y or Colombia
strain. These ORFs encode members of the trans-sialidase family of surface antigens related to the previously
described protective antigen amastigote surface protein 2 (ASP-2). Nevertheless, at the level of antibody
recognition, no cross-reactivity was observed between the ORFs and the previously described ASP-2 from the
Y strain. In immunofluorescence analyses, we observed the presence of epitopes related to both proteins
expressed by amastigotes of seven different strains. In conclusion, our approach allowed us to successfully
identify two novel protective ORFs which we consider interesting for future studies on the immune response
to Chagas’ disease.
Trypanosoma cruzi is an obligate intracellular protozoan par-
asite and the etiologic agent of Chagas’ disease. In spite of the
significant reduction in transmission observed in several coun-
tries in the last 20 years, Chagas’ disease is still a major health
problem for many Latin American countries, afflicting millions
of individuals and causing thousands of deaths every year (34).
The poor prospect of treatment raises the possibility that im-
mune interventions, such as immunization, could be used as an
additional approach to improve disease prevention and treat-
ment efficacy.
Based on the concept of immune interventions, independent
researchers found that the immunization of mice with plasmids
containing T. cruzi open reading frames (ORFs) generated not
only immune responses mediated by antibodies, CD4 and
CD8 type 1 T cells, but also remarkable protective immunity
against otherwise lethal infection with T. cruzi (reviewed in
references 15 and 32). Although prophylactic vaccination was
performed in most studies, immunotherapy also proved feasi-
ble in certain experimental models (16).
Among the ORFs described as capable of eliciting protective
immunity, there are members of the trans-sialidase (TS) family
of antigens expressed on the surface of infective (trypomasti-
gote) or intracellular (amastigote) stages of T. cruzi. Distinct
protective ORFs expressed in trypomastigotes were described
as encoding, for example, the enzymatic domain of T. cruzi TS
(11, 21, 22, 27, 37), the trypomastigote surface antigens (16, 33,
45), or the complement regulatory protein (40). Other protec-
tive ORFs encoded amastigote surface protein 1 (ASP-1) or
ASP-2 expressed in the intracellular stages of the parasite (2, 6,
10, 24, 43).
In addition to the members of the TS family of surface
proteins, ORFs encoding other classes of antigens have also
been reported for their ability to elicit protective immune
responses against experimental mouse infection. Among those
are, for example, the ORFs encoding cruzipain (9, 38), the
LYT-1 antigen (21), the flagellar calcium-binding protein
(Tc24) (16), and a fusion protein containing heat shock protein
70 (HSP70) and the paraflagellar rod protein 2 (PAR-2) (35)
or HSP70 and KMP11 (36).
The examples shown above provided strong support to the
fact that plasmid DNA immunization against T. cruzi infection
can be a useful and relatively simple approach to identify
protective target antigens in the mouse model. However, it is
important to notice that most studies used C57BL/6 or BALB/c
mice for the purpose of vaccination. Although these mice die
when challenged with the infective trypomastigotes of certain
parasite strains, they are not as susceptible to T. cruzi infection
as other mouse strains, such as, for example, A/Sn mice. In
order to study the antigens which provide the protective im-
munity required for vaccination, we have been using this
mouse strain highly susceptible to Chagas’ disease. Infection
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with relatively small doses of the parasites of the Y strain of T.
cruzi leads to 100% death in a period of 30 days or less. Due to
its high susceptibility, we believe that this experimental model
is an interesting one to study antigens capable of generating a
high degree of protective immunity against infection. In this
mouse model, we have recently described how vaccination with
a plasmid containing the ORF encoding an amastigote-specific
antigen (ASP-2) generated specific CD4 Th1 and CD8 Tc1
immune responses. Most importantly, immunization with this
plasmid promoted the survival of approximately 65% of the
mice against a lethal T. cruzi infection (43). Protective immu-
nity of this magnitude could not be duplicated by immuniza-
tion with a plasmid encoding a trypomastigote-specific antigen
(T. cruzi TS) (43, 44). Based on the data obtained following
infection in this mouse model, we considered that perhaps
antigens expressed by the intracellular amastigote forms of T.
cruzi would be better targets for protective immune responses.
Also, host cells containing amastigote nests are critically in-
volved in chronic-phase Chagas’ disease pathology. These in-
fected cells stimulate inflammatory responses considered the
main cause of chronic chagasic pathology and targets for host
protective or, eventually, pathological immune responses (7,
41).
Based on our interest in the amastigote antigens, the present
study had a dual purpose. First, we screened 14 ORFs/antigens
putatively expressed by amastigotes of T. cruzi for their vacci-
nation potential. Second, using a single experimental model of
infection, we could compare the protective potentials of these
different ORFs. The model selected for testing the protective
activity of these ORFs was plasmid DNA immunization of
A/Sn mice highly susceptible to Chagas’ disease followed by
infection with Y strain trypomastigotes.
Because T. cruzi proteome was not available when we initi-
ated this project, we selected the ORFs to be used from three
main source studies. The first study was based on the screening
of a library obtained from amastigote cDNA which identified a
number of T. cruzi ribosomal proteins, flagellar proteins, and
HSPs specifically recognized by immunoglobulins (Igs) from
Chagasic individuals (12). They were (i) ribosomal protein
L7a-like protein, (ii) ribosomal protein S4 homolog, (iii) his-
tone H2b, (iv) HSP, (v) mitochondrial HSP, (vi) elongation
factor 2, (vii) flagellar calcium binding protein 3, and (viii)
PAR-2.
At the time we selected those ORFs, only the flagellar cal-
cium binding protein 3 (Tc24) ORF/antigen had been tested
for its protective efficacy with extremely positive results (16).
During the period we performed our study, Morell et al. (35)
reported that PAR-2- and HSP (HSP70)-fused ORFs could
also elicit a certain degree of immunity against late-stage in-
fection in mice (35). The other ORFs have not been explored
so far for the purpose of vaccination in experimental infection.
A second group of ORFs we selected was based on the study
by Bhatia et al. (5). They described a number of T. cruzi
sequences exhibiting characteristics of membrane-associated
or -secreted proteins (5). Plasmid DNA immunization with
some of these ORFs generated antibodies that reacted with the
surface of amastigotes of T. cruzi (5). The ORFs we selected
from this study were those coding for (i) protein G2, (ii) pro-
tein G4, (iii) elongation factor alpha G5, and (iv) AAA
ATPase-like protein G8. Although the original publication in-
deed described plasmid DNA immunization and the induction
of specific mouse antibody response by these ORFs/antigens,
no data related to immune protection were published there or
elsewhere.
Finally we searched in the recently published T. cruzi pro-
teome/genome for proteins expressed in amastigote forms with
possible identities to the protective antigen ASP-2 (3, 17, 18).
Two ORFs were selected with the characteristics required for
members of the TS family of surface antigens. The primary
structure of each protein based on the predicted amino acid
sequence and computational analysis indicated that both of
them have the predicted signal peptide (SP) and a sialidase-
like domain. One of them has an ASP box motif (SxDxGxTW),
and the other has a putative glycosylphosphatidylinositol (GPI)
addition anchor motif. Although we and others have previously
shown that ASP-2-related ORFs can provide protective immu-
nity following plasmid DNA immunization (2, 6, 10, 13, 24, 43),
we considered that these genes are not identical; therefore,
they constitute new ORFs that had never been tested in ex-
perimental vaccination studies.
MATERIALS AND METHODS
Mice and parasites. Female 5- to 8-week-old A/Sn mice used in this study were
purchased from Centro de Desenvolvimento de Modelos Experimentais (Uni-
versidade Federal de Sa˜o Paulo). Mouse experiments were performed in accor-
dance with the guidelines approved by the ethics committee of Universidade
Federal de Sa˜o Paulo. Parasites of the Y, Sylvio X10/4, Dm28c, CL-Brener,
Tulahuen, G, and Colombian strains of T. cruzi were used (10, 14). All strains
were molecularly typed based on small subunit D7-24S ribosomal DNA se-
quences to confirm their origin (8). Epimastigotes and trypomastigotes were
obtained as described previously (10). Extracellular amastigotes were generated
by incubation of trypomastigotes derived from infected LLC-MK2 cells in LIT
medium for 24 to 48 h at 37°C (1).
Infection with bloodstream trypomastigotes of the Y strain or Colombia strain
and parasitemia were performed as described previously (43). Each mouse was
inoculated intraperitoneally (i.p.) with 150 (Y strain) or 250 (Colombia strain)
trypomastigotes. The values of peak parasitemia of each individual mouse were
log transformed before being compared by one-way analysis of variance followed
by Tukey’s honestly significant difference tests. The log rank test was used to
compare mouse survival rates after challenge with T. cruzi. The differences were
considered significant when the P value was 0.05.
ORF cloning and sequencing. DNA was prepared from T. cruzi epimastigotes
of the Y or CL-Brener strains as described previously (31). PCRs were per-
formed using the enzyme Platinum Pfx DNA polymerase, and the annealing
temperature varied from 52°C to 58°C.
The oligonucleotides used for each ORF are described in Table 1. DNA
fragments were excised from agarose gels, in the DNA products were cloned into
pMOSBlue vector (General Electrics). Automatic sequencing of double-
stranded DNA was carried out using the BigDye terminator cycle sequencing kit
(Perkin-Elmer) on an ABI Prism 377 sequencer (Perkin-Elmer) using initially
the U19 and T7 oligonucleotides and appropriate oligonucleotides designed to
cover the entire sequence.
DNA and predicted amino acid sequences were analyzed using the DNAStar
package, version 5.00 (DNAStar, Inc.). Alignments were produced through the
ClustalW program. Analysis for potential secretory SP and a putative GPI ad-
dition anchor motif were performed at the available websites (http://www.cbs.dtu
.dk/services/SignalP or http://mendel.imp.ac.at/sat/gpi/gpi_server.html).
Eukaryotic expression vector: plasmid generation, purification, and immuni-
zation. Commercially available plasmid pcDNA3 (Invitrogen, San Diego, CA)
was used as the mammalian expression vector. To this plasmid, we added the
nucleotide sequence encoding the mouse Ig  chain SP (IgSP) (6). Isolated T.
cruzi ORFs were subcloned in frame with the IgSP. ORFs ribpS4, rpL7a, h2b,
tc24, par2, and tcg4 and asp-3(5340) were cloned after digestion with KpnI and
EcoRI. ORFs hsp70 and ef2 were cloned after digestion with KpnI and XbaI.
ORFs mtp70, tcg2, tcg5, and tcg8 were cloned after digestion with KpnI and
BamHI. ORF asp-4(7015) was cloned after digestion with BamHI and XbaI.
Other plasmids of T. cruzi ASP-2 (pIgSP-clone9) of the Y strain or Colombian
strain (pIgSP-clone22) were generated as described earlier (6, 10).
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Plasmids were produced in E. coli DH5 and purified on cesium chloride
density gradients according to standard protocols. Each plasmid DNA was di-
luted in sterile phosphate-buffered saline to a concentration of 1.5 mg/ml, and
A/Sn mice were immunized according to a protocol described earlier (11).
Seventy-five micrograms of plasmid DNA was injected intramuscularly at the
same sites used for a cardiotoxin injection given 5 days earlier. Two boosting
immunizations consisted of the same amount of plasmid DNA injected intra-
muscularly 3 and 5 weeks after the first dose. One to 2 weeks after the last dose,
mice were bled or challenged with bloodstream trypomastigotes.
IFA. HeLa cells (1.5  104) were plated in RPMI medium containing 10%
fetal bovine serum (Invitrogen) in 24-well plates (Costar) containing 13-mm
round coverslips at 37°C in a humidified atmosphere containing 5% CO2. Ten
parasites per target cell was the dose used for infection with trypomastigotes of
the Y strain. After 48 h, HeLa cells fixed with a paraformaldehyde solution (2%
[vol/vol]) for 20 min at room temperature. Parasite fixation and indirect immu-
nofluorescence assay (IFA) staining were performed exactly as described earlier
(6, 10). IFA images were acquired with a Zeiss Axiovert microscope attached to
a Bio-Rad 1024UV confocal microscope using a 100 1.4 differential interfer-
ence contrast PlanApo objective.
Bacterial recombinant proteins: plasmid generation, E. coli expression, and
purification. As a bacterial expression vector, we used the commercial vector
pET28A (Novagen, Madison, WI). A plasmid was generated based on the se-
quence of ASP-3(5340). The asp-3(5340) gene was amplified by PCR using the
forward and reverse oligonucleotides indicated in Table 1. The amplified PCR
products were cloned into the pMOSBlue vector, removed by treatment with
restriction enzymes BamHI and EcoRI, and ligated into the pET28A vector
treated with the same enzymes.
Plasmids were transformed into E. coli BL21 expression host cells (Novagen).
Protein expression of His-tagged 65-kDa protein (His-65kDa; ASP-2, Y strain)
or His-63kDa [ASP-asp-3(5340)] was obtained as described previously (2, 6, 10,
13). The purity of recombinant protein was determined by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). An SDS molecular
weight marker kit (Sigma) and a Benchmarker prestained protein ladder (In-
vitrogen) were used as protein standards.
ELISA and immunoblotting. Antibodies were detected by enzyme-linked im-
munosorbent assay (ELISA) using polystyrene microtiter plates (high binding;
Costar) coated with the recombinant protein His-65kDa for ASP-2 (6) or His-
63kDa for ASP-3(5340). The experimental procedures have been previously
described in detail in references 6 and 10.
For immunoblotting, extracellular amastigotes of T. cruzi were obtained as
described above. The parasite concentration was adjusted to 109 parasites per ml.
Parasite extracts were obtained by treating the parasites with a solution of PBS
containing a final concentration of 1% (vol/vol) NP-40 and proteolytic enzyme
inhibitors (1 mM phenylmethylsulfonyl fluoride and 1 mM iodoacetamide ).
After centrifugation, the supernatants were collected, mixed with SDS-PAGE
sample buffer containing 2-mercaptoethanol, and boiled. The amount of liquid
corresponding to 107 parasites was loaded for SDS-PAGE and transferred to
nitrocellulose membranes (Millipore). Antibody staining was performed with a
pool of sera from mice immunized with plasmid DNA containing ORF asp-
3(5340) diluted 1:500 or asp-4(7015) diluted 1:800. Bound antibodies were de-
tected by incubating the immunoblot membranes with goat anti-mouse IgG
coupled to peroxidase diluted 1:1,200 [asp-3(5340)] or 1:1,600 [asp-4(7015)]
(Invitrogen) followed by development of the chemoluminescent reaction with
Super Signal West Pico chemiluminescent substrate (Pierce), as described by the
manufacturer, and exposure to Hyperfilm.
Nucleotide sequence accession numbers. Nucleotide sequence data reported
are available in the Third Party Annotation section of the DDBJ/EMBL/Gen-
Bank databases under the accession numbers BK006544 to BK006557 (Table 2).
RESULTS
As an attempt to characterize new antigens expressed by Y
strain amastigotes of T. cruzi, we selected several ORFs based
on previous studies of immunogenicity performed either with
mice or humans with T. cruzi immunity (5, 12). A detailed
rationale for the selected ORFs is provided in the introduction.
Thirteen ORFs were PCR amplified from genomic DNA
isolated from the Y strain. One ORF (gene identification no.
5340.t00006 and GenBank accession no. XM-804480) could
not be isolated from the genomic DNA of the Y strain. In this
case, we used genomic DNA from the CL-Brener strain. In
many cases, computational analyses were used to determine
whether the predicted amino acid sequences of these ORFs
had a highly probable SP. For these ORFs, we prepared 5
oligonucleotides which excluded the sequence coding for the
putative SP. As depicted in Table 2, each predicted amino acid
sequence showed a high degree of identity to the previously
described ORF, varying from 96 to 100%.
These 14 ORFs were subcloned into the eukaryotic expres-
sion vector pcDNA3 containing the nucleotide sequence en-
coding the mouse IgSP (6). We used this vector based on
experiments in which we found that the presence of a eukary-
otic signal peptide improved the immunogenicity of several
ORFs when delivered by genetic immunization with plasmids
or viruses (M. M. Rodrigues, unpublished observations).
Groups of A/Sn mice were immunized with each of these
plasmids. We decided to immunize each mouse group with a
single plasmid, not a pool of plasmids, due to a previous ob-
servation that DNA vaccination with a mixture of plasmids
may interfere with the immune response of the mice (39).
TABLE 1. Oligonucleotides used in the present study
ORF
Oligonucleotide sequence
Forward Reverse
ribpS4 GGAGGTACCATGACCAAG AAGCACCTG CAGAATTCCCTATTTTCGTGCCTTGCG
rpl7a GGAGGTACCATGCCCGGCAAGGAAGTG CAGAATTCCTCACATTACGGCGGCAGC
h2b GGAGGTACCATGGCCACCCCCAAGAGC CAGAATTCCCTAACTAGAGGCGTGCGA
hsp70 GGAGGTACCATGACGTACGAGGGAGCC CAGAATTCCTCAGTCCACTTCCTCCAC
mtp70 GGAGGTACCATGTTCGCTCGTCGTTTG CAGAATTCCTTACTGCTTCTGCTGATC
ef2 GGAGGTACCCATGGCAAG TCGACTTG CAGAATTCCCCAGTGGTCAAAGACACA
tc24 GGAGGTACCATGGGTGCTTGTGGGTCG CAGAATTCCTCACGCGCTCTCCGGCAC
par2 GGAGGTACCATGAGCTACAAGGAGGCA CAGAATTCC TTACTGTGTGATCTGCTG
tcg2 GGAGGTACCATGTCGCTTTCATTTATC CAGAATTCCTTTGTACTCCTTTTGCCAAC
tcg4 GGAGGTACCATGTCAGCCAAGGCTCCC CAGAATTCCCTACTTTCCAAGCGCCTT
tcg5 GGAGGTACCATGGGGAAGGAAAAGGTG CAGAATTCCTCACTTCTTAGCGGCCTT
tcg8 GGAGGTACCATGTCCGATAACCATCAA AGCGGCCGCTCACTGTGGTACAACGCT
asp-3(5340) GGAGGTACCGATGGAAGTAGTGGGGCA CAGAATTCCCCCCAGAAGCTCTGCGTC
asp-4(7015) GAATTCGAGAACAGTGTTTCAGGG GCCGCTCGAACCGACACCCGTTGCTCC
asp-3(5340) (recombinant
protein)
GGGGGATCCGATGGAAGTAGTGGGGCA GGGGAATTCCCCCAGAAGCTCTGCGTC
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Although this approach was more laborious, the results were
more decisive.
After the third immunizing dose, the animals were bled and
their sera were used to react by IFA with cells of the different
stages of T. cruzi. As shown in Table 3, except for the mice
immunized with the control empty vector or the par-2 ORF, all
other immune sera recognized amastigotes. The lack of im-
mune reactivity of the sera from par-2-immunized mice cannot
be attributed to the absence of specific antibodies because they
clearly recognized the other two forms of the parasite (trypo-
mastigotes and epimastigotes).
Immune sera from mice immunized with three other ORFs
(tc24, hsp70, and mtp70) recognized all three developmental
forms of T. cruzi. Immunization with the other 11 ORFs elic-
ited stage-specific antibodies to amastigotes. We concluded
that the ORFs we selected were in most cases amastigote stage
specific or contain predominantly amastigote stage-specific
epitopes.
The presence of T. cruzi-specific antibodies was taken as a
strong indication that the antigens had been produced and
were available to the immune system. DNA-immunized mice
were then challenged i.p. with a lethal dose of Y strain trypo-
mastigotes. A group of mice injected with empty pcDNA3 was
always used as a control, and their parasitemia and mortality
were considered for statistical comparison. As shown in Table
4, all control mice succumbed to infection. Their deaths oc-
curred less than 30 days after challenge in 98.39% of the cases.
pcDNA3-injected mice challenged in parallel with each plas-
mid were used to establish the statistical significance of the
other mouse groups based on the log rank test for survival rates
after T. cruzi infection. Complete protection was only consid-
TABLE 2. Summary of the ORFs used in the present study
ORF Product description
GenBank accession no. Amino acid
identity (%) ReferencesPrevious This study
ribpS4 Ribosomal protein S4 homolog AF005904 BK006552 100 25
rpl7a Ribosomal protein L7a-like protein AF316150 BK006549 98 12
h2b Histone H2b X60982 BK006545 100 23
hsp70 HSP M26595 BK006546 98 19
mtp70 Mitochondrial HSP M73627 BK006547 99 20
ef2 Elongation factor 2 D50806 BK006544 99
tc24 Flagellar calcium binding protein 3 AF192980 BK006553 99
par2 Paraflagellar rod protein 2 M97548 BK006548 99 4
tcg2 Protein G2 AY727915 BK006557 96 5
tcg4 Protein G4 AY727917 BK006554 98 5
tcg5 Elongation factor alpha G5 AY727921 BK006555 99 5
tcg8 AAA ATPase-like protein G8 AY727920 BK006556 99 5
asp-3(5340) Strain CL-Brener trans-sialidase XM_804480 BK006550 96 3, 17
asp-4(7015) Strain CL-Brener trans-sialidase XM_803731 BK006551 97 3, 17
asp-2(Y strain) Amastigote surface protein 2 AY186572 6
TABLE 3. Reactivity by IFA of sera from plasmid
DNA-immunized A/Sn mice to different
developmental stages of T. cruzi
T. cruzi ORF with
plasmid pIgSPa
Reactivity to developmental stage:
Epimastigote Amastigote Trypomastigote
Empty Negative Negative Negative
ribpS4 Negative Positive Negative
rpl7a Negative Positive Negative
h2b Negative Positive Negative
hsp70 Positive Positive Positive
mtp70 Positive Positive Positive
ef2 Negative Positive Negative
tc24 Positive Positive Positive
par2 Positive Negative Positive
tcg2 Negative Positive Negative
tcg4 Negative Positive Negative
tcg5 Negative Positive Negative
tcg8 Negative Positive Negative
asp-3(5340) Negative Positive Negative
asp-4(7015) Negative Positive Negative
asp-2 (Y strain) Negative Positive Negative
a Sera from mice immunized three times with the indicated ORFs were used
for the IFA reaction.
TABLE 4. Results of A/Sn mice vaccination with the different
ORFs and challenge with blood trypomastigotes from the
Y strain of T. cruzia
T. cruzi ORF with
plasmid pIgSP
No. of
immunized
animals
% Survival at: P value
(log rank test)b30 days 60 days
Empty 62 1.61 0
ribpS4 6 0 0 0.0055
rpl7a 6 0 0 0.0024
h2b 6 0 0 0.2759
hsp70 6 0 0 0.1787
mtp70 6 0 0 0.0619
ef2 6 0 0 0.4579
tc24 6 33.33 16.66 0.0265
par2 6 16.66 0 0.0519
tcg2 6 0 0 0.3450
tcg 4 4 0 0 0.5520
tcg 5 5 0 0 0.0014
tcg 8 6 16.66 0 0.0271
asp-3(5340) 6 83.33 50 0.0005
asp-4(7015) 6 83.33 66.66 0.0061
asp-2 (Y strain) 7 71.43 57.14 0.0007
a A/Sn mice were immunized as described in Materials and Methods with
pIgSP plasmids containing the indicated T. cruzi ORFs. Results are representa-
tive of two or more experiments performed with each plasmid.
b Kaplan-Meier curves for survival of mice immunized with the different plas-
mids were compared to those for pcDNA3-injected animals using the log rank
test. Data are representative of two or more experiments performed with each
plasmid. Boldface numbers represent statistically significant differences (P 
0.05).
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ered for animals that survived more than 60 days after chal-
lenge. The mice which did not die after this period were sac-
rificed.
Seven of the 15 ORFs tested failed to induce any degree of
immunity as determined by the survival rates after infection
(P  0.05, log rank test [Table 4]). Five other ORFs provided
a certain degree of protective immunity, as indicated by a
significant delay in mortality compared to control pcDNA3-
immunized animals challenged in parallel. These ORFs were
(i) rpl7a (P  0.0024), (ii) ribpS4 (P  0.0055), (iii) tcg5 (P 
0.0014), (iv) tcg8 (P  0.0271), and (v) tc24 (P  0.0265).
However, only a few mice survived more than 60 days after
challenge.
Immunization with two ORFs generated higher immunity,
not only by delaying cumulative mortality significantly but also
by allowing 50% or more of the challenged animals to survive.
These proteins were previously denominated ASP-related pro-
teins (gene identification no. 5340.t00006 or 7015.t00004 [2]
and GenBank accession no. XM_804480 or XM_803731, re-
spectively). As mentioned above, based on the proteome anal-
ysis, these two proteins were expressed by amastigotes of T.
cruzi. Through their predicted amino acid sequences, both
genes encode members of the TS family containing 674 or 777
amino acids (aa), respectively (3). We denominated these an-
tigens ASP-3(5340) and ASP-4(7015) due to their presence on
amastigotes and their previous gene identification. In Fig. 1, we
show a schematic representation of the primary structure of
each protein based on the predicted amino acid sequence and
computational analysis. Both of them have predicted SP and a
sialidase-like domain. ASP-3(5340) has an ASP box motif
(SxDxGxTW) between aa 344 and 351, and asp-4(7015) has a
putative GPI addition anchor motif (Fig. 1A and C, respec-
tively). On the same figure, we also show the regions of each
ORF that were subcloned into our eukaryotic expression vec-
tor. We removed the nucleotide sequences encoding the pre-
dicted T. cruzi SP or GPI addition anchor motifs (Fig. 1B and
D). These new ORFs were then subcloned in frame with the
sequence encoding mouse IgSP.
Table 5 shows the identities found when the ORFs’ nucle-
otide and predicted amino acid sequences were compared with
selected sequences of previously described ORFs of members
of the TS family expressed by amastigotes of T. cruzi. At the
nucleotide or amino acid level, asp-3(5340) displayed a high
degree of identity to isoforms of asp-2 recently cloned from the
cDNA of amastigotes of the Sylvio X10/4 or G strain, respec-
tively (10). The nucleotide identities between asp-3(5340) and
the asp-2 from the Y strain (clone 9 or clone 13) were 58.2 and
59.8%, respectively (6). At the level of predicted amino acid
sequence, the identities between asp-3(5340) and the asp-2
from the Y strain (clone 9 or clone 13) were 43.8 and 45.8%,
respectively. Finally, the identities at both nucleotide and pre-
dicted amino acid levels to asp-4(7015) were very limited.
asp-4(7015) displays a large number of copies of similar
ORFs in the parasite genome (17). Twenty of the putative
ORFs have an identity at the level of amino acid predicted
sequences of 80%. The amino acid identity to the other asp
was limited, varying from 15.2% [asp-2, G strain] to 23.2%
(asp-2, clone 13, Y strain [Table 5]). It is important to note that
FIG. 1. Schematic representation of the predicted amino acid se-
quences encoded by ORFs asp-3(5340) and asp-4(7015). Panels A and
C show the schematic representation based on the predicted amino
acid sequences of ORFs initially described (GenBank accession no.
XM_804480.1 and XM_803731). Panels B and D show the predicted
amino acid sequences of ORFs that we subcloned into the pcDNA3
eukaryotic expression vector.
TABLE 5. Estimation of nucleotide and predicted amino acid identities among products of selected ORFs expressed by T. cruzi amastigotes
Strain and protein
% Nucleotide or predicted amino acid sequence identitya
CL-Brener
ASP-3(5340)b
Sylvio X10/4
ASP-2c G ASP-2
d Y ASP-2
(clone 9)e
Y ASP-2
(clone 13)f ASP-4(7015)
g
CL-Brener ASP-3(5340) 93.8 91.8 58.2 59.8 28.1
Sylvio X10/4 ASP-2 87.7 94.7 58.9 61.5 25.5
G ASP-2 72.8 77.3 56.8 59.2 24.3
Y ASP-2 (clone 9) 43.8 44.7 40.1 79.4 28.9
Y ASP-2 (clone 13) 45.4 48.1 43.2 69.9 27.5
ASP-4(7015) 21.7 18.4 15.2 22.3 23.2
a Identities were calculated by the ClustalW alignment. Boldface values represent nucleotide sequence identity; lightface values represent predicted amino acid
identity.
b GenBank accession no. BK006550.
c GenBank accession no. EF579923.1 (10).
d GenBank accession no. EF579923.1 (10).
e GenBank accession no. AY186572.1 (6).
f GenBank accession no. AY186574 (6).
g GenBank accession no. BK006551.
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asp-4(7015) contains the epitope TsKb-21 (ANYNFTLV),
which has been shown to be highly recognized during experi-
mental infection of C57BL/6 mice with the Brazil strain of T.
cruzi (Fig. 1C and D and reference 30).
With IFA, we observed that sera from asp-3(5340) or asp-
4(7015) DNA-immunized mice reacted with Y strain amasti-
gotes grown in cultured HeLa cells (Fig. 2A). An immunoblot
showed that sera from asp-3(5340) DNA-immunized mice rec-
ognized bands of approximately 72 kDa and 57 kDa when
reacted with extracts of extracellular amastigotes of the Y
strain of T. cruzi. The immune sera from mice immunized with
asp-4(7015) probed with the same parasite extract recognized
polypeptides of approximately 74 kDa and 37 kDa (Fig. 2B).
Control sera from immunized pcDNA3 failed to recognize any
amastigote protein by immunoblotting (data not shown).
Due to the limited identity in the predicted primary amino
acid sequence between asp-3(5340), asp-4(7015), and asp-2 (Y
strain), we predicted that cross-reactivity at the immunological
level would be restricted. To test this hypothesis, we used
pooled sera from mice immunized with each ORF to react with
two recombinant proteins in ELISA. As shown in Fig. 2C, sera
from A/Sn mice immunized with asp-2 reacted with recom-
binant ASP-2 (His-65kDa) but not with recombinant ASP-
3(5340) (His-63kDa). Inversely, sera from mice immunized
with asp-3(5340) reacted with recombinant ASP-3(5340) (His-
63kDa) but not with recombinant ASP-2 (His-65kDa). Sera
from mice immunized with asp-4(7015) failed to react with
either recombinant protein. The lack of reactivity cannot be
attributed to low antibody concentrations because these sera
recognized amastigotes by IFA (Table 3). We concluded that
although all three proteins are members of the TS family,
containing a sialidase-like domain, and are expressed as amas-
tigote-specific antigens, they share limited antigenic cross-re-
activity, at least at the level of antibody recognition.
We also sought to determine whether sera from mice
immunized with ORF asp-3(5340) or asp-4(7015) could rec-
ognize amastigotes of different T. cruzi strains. For that
purpose, IFA was carried out using amastigotes of seven
distinct strains as targets. The results, summarized in Table
6, show that immune sera from asp-3(5340), asp-4(7015), or
asp-2 DNA-immunized mice recognized amastigotes of all
different strains, indicating the presence of the antigen or
cross-reactive epitopes.
Finally, we determined whether protective immunity elicited
by these two ORFs could also be obtained against a challenge
with a second strain of T. cruzi. For that purpose, A/Sn mice
were vaccinated with plasmids containing asp-3(5340), asp-
4(7015), or asp-2 (clone 22, Colombian strain). Parasitemia
and mortality were monitored after challenge with trypomas-
tigotes of the Colombia strain (14). Only mice vaccinated with
asp-2 displayed a significant reduction of the parasitemia com-
pared to pcDNA3-injected animals (Fig. 3A; P  0.01). How-
ever, the mortality rates of asp-3(5340), asp-4(7015), and
asp-2 DNA-vaccinated mice were significantly delayed in
comparison to those of animals injected with pcDNA3 (Fig.
3B; P 	 0.0007, P 	 0.0018, and P 	 0.0007, respectively).
No difference was observed among the groups that received
each asp (P  0.05, log rank test). We concluded from this
experiment that vaccination with plasmids containing asp-
FIG. 2. IFA, immunoblotting, and ELISA using antibodies specific
for ASP-3(5340) and ASP-4(7015). (A) Intracellular amastigotes were
analyzed by IFA using antibodies specific for ASP-3(5340) and ASP-
4(7015). HeLa cells infected for 48 h with parasites of the Y strain of
T. cruzi were incubated with a pool of sera derived from mice immu-
nized with plasmids containing ORF asp-3(5340) or asp-4(7015) and
imaged under fluorescence. Blue, DAPI staining; green, fluorescein
isothiocyanate-labeled goat anti-mouse Ig. Magnification bars, 10 
m.
(B) Extracellular amastigote extracts (equivalent to 107 parasites) of
the Y strain were loaded into each lane for an SDS-PAGE performed
under reducing conditions. Immunoblot strips were incubated with a
pool of sera derived from mice immunized with plasmids containing
ORF asp-3(5340) or asp-4(7015) diluted 1:500 or 1:800, respectively.
(C) Pools of sera derived from mice immunized with plasmids con-
taining ORF asp-2, asp-3(5340), or asp-4(7015) were diluted 1:400.
Results are expressed as the average  standard deviation of three
independent experiments.
TABLE 6. Results of the IFA using sera from plasmid DNA-
vaccinated mice against amastigotes of different T. cruzi strains
Amastigote
strain
IFA result for T. cruzi ORF:
asp-3(5340) asp-4(7015) asp-2 Empty
Y Positive Positive Positive Negative
Colombian Positive Positive Positive Negative
Sylvio X10/4 Positive Positive Positive Negative
G Positive Positive Positive Negative
CL Brener Positive Positive Positive Negative
Tulahue´n Positive Positive Positive Negative
Dm28c Positive Positive Positive Negative
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3(5340) or asp-4(7015) indeed provided a certain degree of
protective immunity to A/Sn mice highly susceptible to Cha-
gas’ disease following a lethal challenge with a second un-
related strain of T. cruzi.
DISCUSSION
The aims of the present study were first to screen 14 ORFs/
antigens putatively expressed by amastigotes of T. cruzi for
their vaccination potential and second to compare the protec-
tive potential of these different ORFs following plasmid DNA
immunization of A/Sn mice highly susceptible to Chagas’ dis-
ease challenged with Y strain trypomastigotes.
Using the immune sera of plasmid DNA-vaccinated mice,
we confirmed that in fact most of the antigens selected were
stage-specific amastigote antigens. Only one ORF/antigen was
not expressed by amastigotes (par-2). Three other antigens
were expressed in the three developmental stages tested. The
presence of specific antibodies served as a guide to confirm
successful protein expression and immunogenicity. Although
protein expression and antigenic priming were observed, many
of these ORFs failed to provide a detectable degree of pro-
tective immunity. These ORFs were h2b, hsp70, mtp70, ef2,
par2, tcg2, and tcg4. Our observations confirm and extend a
recent publication from Morell et al. (35), who reported that
par2 or hsp70 ORFs in mice failed to promote a detectable
degree of protective immunity when injected individually.
However, when these authors used a fused gene containing
both ORFs for vaccination, immunity to late-stage infection
was observed (35). Together with our results, they indicated
that perhaps plasmid DNA immunization with par-2 ORF in-
dividually is not as effective as a previously described immuni-
zation method using recombinant protein PAR-2 (28, 46).
The most relevant part of our study was the fact that after a
lethal challenge with Y strain trypomastigotes of T. cruzi, we
observed that several antigens induced a certain degree of
immunity, as measured by a delay in mouse mortality. Immu-
nization with plasmids containing ORFs RpL7a, RibpS4, TcG5,
Tc24, and TcG8 caused a significant delay in mouse mortality
(Table 4). Among those, only ORF Tc24 had been previously
described for its ability to elicit protective immunity against a
lethal T. cruzi infection (16). Therefore, our results are the first
to suggest that these other ORFs/antigens can generate a cer-
tain degree of immunity against experimental T. cruzi infec-
tion. Nevertheless, it is important to note that in rare cases, the
mice survived more than 30 days after challenge. The fact that
the protective potential of these five ORFs is limited in this
mouse model of infection should not be seen as a completely
negative result when evaluating the importance of ORFs as a
target of protective immunity. Perhaps they can be further
explored using other genetically distinct mouse or parasite
strains. Also, the use of stronger genetic vectors, such as ade-
novirus, or the use of recombinant proteins and Toll-like re-
ceptor agonist adjuvants, such as CpG oligodeoxynucleotides,
might help to increase their immune-protective potential (2,
13, 27, 29).
Two ORFs/antigens elicited protective immunity capable of
delaying mouse mortality and providing complete protection to
a fraction of mice infected with two distinct strains of T. cruzi.
These antigens are members of the TS family of surface pro-
teins, and their immunological potential has been explored
here for the first time. Although one of them, ASP-3(5340),
shares a certain degree (43.8 to 45.4%) of identity at the level
of primary structure with a previously described stage-specific
antigen (ASP-2 of the Y strain), we did not observe cross-
FIG. 3. Trypomastigote-induced parasitemia and mortality in A/Sn
mice immunized with plasmids containing asp-related ORFs expressed
in amastigotes of T. cruzi. A/Sn mice were immunized with plasmid
pIgSP-asp-3(5340), pIgSp-asp-4(7015), pIgSP-clone22 (Colombian
strain), or pcDNA3. Fourteen days after the last immunization, mice
were challenged i.p. with 250 bloodstream trypomastigotes of the Co-
lombia strain. In the top panel, the course of infection was estimated
by the number of trypomastigotes per ml of blood. Results represent
the mean  standard deviation obtained from five or six mice immu-
nized with each plasmid. At the peak of infection, the parasitemias of
mice immunized with each plasmid were compared by one-way anal-
ysis of variance and Tukey’s honestly significant difference tests. The
peak parasitemias of mice immunized with pIgSP-asp-3(5340) or
pIgSp-asp-4(7015) were not different from those of animals injected
with pcDNA3 (P  0.05 in both cases). However, a significant differ-
ence was detected when we compared the peak parasitemias of mice
immunized with pcDNA3 or pIgSP-clone22 (Colombian strain) (P 
0.01). In the bottom panel, Kaplan-Meier curves for the survival of
mice immunized with pIgSP-asp-3(5340), pIgSp-asp-4(7015), pIgSP-
clone22 (Colombian strain), or pcDNA3. The results of the compari-
son were as follows: (i) pcDNA3  pIgSP-asp-3(5340), P	 0.0007; (ii)
pcDNA3  pIgSP-asp-4(7015), P 	 0.0018; (iii) pcDNA3  pIgSP-
clone22 (Colombian strain), P 	 0.0007; (iv) pIgSP-asp-4(7015) 
pIgSP-asp-3(5340), P  0.05; (v) pIgSP-asp-3(5340)  pIgSP-clone22,
P  0.05; and (vi) pIgSP-asp-4(7015)  pIgSP-clone22, P  0.05. Data
are representative of two experiments performed with similar results.
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reactivity between both as recognized by specific antibodies
(Fig. 2C). Also, there was no recognition of the 83-kDa antigen
by immunoblot analysis (Fig. 2B). The primary structure of the
second antigen, ASP-4(7015), shares very limited identity at
the level of primary structure with the other ASP, and sera
from immune mice failed to recognize either of the recombi-
nant proteins representing them (Fig. 2C).
Analyses with IFA showed that amastigotes from seven par-
asite strains express epitopes related to each of these new
antigens as recognized by immune sera. Although these results
are suggestive of their expression in other parasite strains, until
these ORFs are cloned and sequenced, it will not be possible to
establish their structural relationship with certainty.
The results of protective immunity obtained following vac-
cination with these two ORFs are important because in this
mouse model only vaccination with the asp-2 ORF had been
successful so far (2, 13, 43). In contrast, vaccination with a
plasmid containing the ORF encoding the catalytic domain of
T. cruzi TS failed to promote a similar degree of protective
immunity (43, 44). The same plasmid has been shown in many
instances to be highly protective in BALB/c mice challenged
with parasites of the Y or Tulahuen strain of T. cruzi (11,
22, 27).
In the present study, we did not delve more deeply into the
nature of the immunological mechanisms operating in DNA-
vaccinated mice. Nevertheless, it is plausible to propose that
they are most likely related to T-cell-mediated immune re-
sponses, as antibodies have never been described as being
efficient against the intracellular form of T. cruzi. In contrast,
CD4 Th1 and CD8 Tc1 are often seen as important mecha-
nisms of immunity following infection with or vaccination
against T. cruzi (26, 27, 29, 30, 37, 42, 43). Nevertheless, it is
very important to notice that in this mouse model even a strong
CD4 Th1 response against an important antigen such as the
catalytic domain of TS did not confer a significant degree of
protective immunity (43, 44). Antigen-specific CD4 T cells
capable of producing considerable amounts of gamma inter-
feron and proliferating in vitro failed to protect these animals
(44). Therefore, other mechanisms such as CD8 T cells might
be critical for the protection of these highly susceptible A/Sn
mice. Indeed protected A/Sn mice vaccinated with either plas-
mid DNA or a recombinant protein expressing the ASP-2
antigen became completely susceptible to infection when de-
pleted of CD8 T cells (2, 43). Our data clearly point to an
essential role for CD8 T cells for protective immunity. We
believe that the appropriate experimental approach to initiate
studies on the mechanisms of immunity generated by these
new ORFs/antigens would be in vivo depletion of CD4 or
CD8 T cells before challenge. Immunological analyses based
on antibody titers and CD4 T-cell activation (proliferative
responses and gamma interferon secretion in vitro) have not
added much to the understanding of this experimental model
so far (44).
In summary, our study shows that the availability of infor-
mation on the amastigote-expressed ORFs of T. cruzi coupled
with plasmid DNA immunization can be an alternative method
to screen and compare for new antigen targets of protective
immune responses against experimental infection. These anti-
gens can then be used in different immunological studies to aid
in understanding the complex immunopathology observed dur-
ing Chagas’ disease.
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